A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.

Inclusion Criteria: * Patient must provide signed, written informed consent prior to any study-related procedures being performed. * Patient is between 18 and 65 years of age, inclusive. * Patient has documented Fabry disease. * Patient has received bi-weekly 1 mg/kg infusions of Fabrazyme for at least 6 months prior to enrollment into the study. * Patient has not experienced moderate or severe infusion-associated reactions (IARs) from Fabrazyme infusions, which were also associated with a rate reduction, within 3 months prior to enrollment into the study. * Patient has been receiving chronic hemodialysis for treatment of end-stage renal insufficiency for at least 3 months prior to enrollment into the study. * Patient has good vascular access for hemodialysis. * Patient has not and will not have any other (investigational) drug(s) infused during their hemodialysis, and is expected to have a stable concomitant medication regimen at all PK assessments. Exclusion Criteria: * Patient's hemoglobin is \< 9 g/100 mL at Screening/Baseline. * Patient has a clinically significant organic disease or an unstable condition that, in the opinion of the Investigator, would preclude participation in the study. * Patient has a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance. * Patient has participated in a study employing an investigational drug within 30 days prior to the start of their participation in this study. * Patient is unwilling to comply with the requirements of the protocol.